Patel PA, Zyczynski TM, Beard SM, Earnshaw SR, McDade CL, Zimovetz E. A European multicountry comparison of the cost-effectiveness of iodixanol versus iohexol based on the results of the NEPHRIC clinical trial. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Farkouh RA, Earnshaw SR, Watson ME, Maroudos P. Short-term cost-effectiveness of hla*b-5701 testing prior to initiation of abacavir. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Disease Society of America 46th Annual Meeting; October 2008.
Earnshaw SR, Graham CN, Irish WD, Sato R, Schnitzler MA. Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation. J Am Soc Nephrol. 2008 Sep 1;19(9):1807-16.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Sunyecz J, Silberman C, Poston S, Earnshaw SR. Cost-effectiveness of ibandronate therapy for women with postmenopausal osteoporosis with respect to nonvertebral fracture efficacy. Poster presented at the 30th Annual Meeting of the American Society for Bone and Mineral Research; September 2008.
Farkouh RA, Earnshaw SR, Kauf TL, Watson ME, Maroudas P. Cost-effectiveness of hla*b-5701 testing prior to initiation of abacavir sulfate. Poster presented at the 17th International AIDS Conference; August 2008.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AR. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008 Jul 1;11(4):563-74.
Graham CN, Earnshaw SR, Raymond V. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis in Canada. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A98.
Bell CF, McDade CL, Black L, Earnshaw SR, Kattan MW. Considerations for modeling the cost-effectiveness of preventative prostate cancer treatments. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada.
Earnshaw SR, Candrilli SD. The nuts and bolts of measuring medication adherence: a practical approach. Poster presented at the 20th Annual Meeting of the American Managed Care Pharmacy; April 2008.
Earnshaw SR, Beard SM. Supporting reimbursement of pharmaceuticals. Presented at the INFORMS Conference on OR Practice; April 2008.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Earnshaw SR, Graham CN, Amonkar MM, Poston SA, Barr CE. Cost-effectiveness of ibandronate intravenous injection in the treatment of US women with postmenopausal osteoporosis. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Earnshaw SR, Pignone M, Tice J, Pletcher M. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Poster presented at the Annual Meeting of the Institute for Operations Research and the Management Sciences; November 2006.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Cowell W, Amonkar M, Cooper A, Earnshaw SR, Beard SM, Lynch N, Middelhoven H. Ibandronate vs. alendrolate: a cost-effectiveness analysis using persist results. Poster presented at the 2006 American College of Rheumatology Scientific Meeting; November 2006.
Shearer A, Gazzard B, Graham CN, Davis EA, Mauskopf J, Kitahata M, Saag MS, Earnshaw SR. Simulation modeling of adherence and resistance on long-term outcomes in HIV. Poster presented at the Infectious Disease Society of America 44th Annual Meeting; October 15, 2006.
Graham CN, Earnshaw SR, Smith DG, Hogue S, Gitchell J, Marsh H, Becker W, Saunders M. Assessing the impact of smoking cessation therapies on a managed care organization's budget. Poster presented at the Academy of Managed Care Pharmacy Educational Conference; October 7, 2006.
Earnshaw SR, Beard SM, Lynch NO, Cooper A, Cowell W, Middelhoven H. A comparison of the cost-effectiveness of bisphosphonates using persistence data from a UK propsective rct. Poster presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research; September 19, 2006.
Schnitzler MA, Earnshaw SR, Graham CN, Irish WD, Sato R. Lifetime cost-effectiveness of calcineruin inhibitor-free immunosuppressive treatment after de novo renal transplantation. Poster presented at the World Transplant Congress; July 27, 2006.
Earnshaw SR, Beard SM, Lynch NO, Cowell W. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK. Poster presented at the European League Against Rheumatism Annual European Congress of Rheumatology; June 24, 2006.
Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson K. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA.
Earnshaw SR, Moride Y, Moshyk A, Rochon S. Cost-effectiveness of macugen compared to photodynamic therapy (PDT) with verteporfin and standard care in the treatment of subfoveal wet age-related macular degeneration (AMD) in the elderly in Canada. Poster presented at the Third Annual Canadian Joint Therapeutics Congress, Canadian Association for Population Therapeutics; May 13, 2006. Toronto, Canada.
Bell CF, Graham JB, Earnshaw SR, Oleen-Burkey M, Castelli-Haley J, Johnson KP. Assessing the cost-effectiveness of immunomodulatory therapies for relapsing-remitting multiple sclerosis based on long-term data. Value Health. 2006 May 1;9(3):A81-2.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Wilson MR, Joshi AV. Short-term cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Value Health. 2006 May 1;9(3):A8.
Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.
Earnshaw SR, Joshi AV, Wilson MR. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US managed care perspective. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 7, 2006.
Earnshaw SR, Gricar J. Good practices for high quality decision analytic models. Poster presented at the Academy of Managed Care Pharmacy 18th Annual Meeting; April 6, 2006.
Javitt JC, Earnshaw SR, Graham CN, Brogan AJ, Zlateva GP, Pleil AM. Cost-effectiveness of Macugen versus no treatment in age-related macular degeneration patients. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting; April 2006.
Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 Mar 7;144(5):326-36.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2006 World Ophthalmology Congress; February 2006. Previously presented at the ISPOR 8th Annual European Congress.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.